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Use of physiologically based kinetic (PBK) modeling to study interindividual human 1 variation and species differences in plasma concentrations of quercetin and its metabolites
underlying these health effects. However, where most of these in vitro studies are performed with 6 the aglycone, this form is hardly available in vivo due to extensive metabolism of the flavonoid 7 aglycone in the intestine and liver. As a result, mainly flavonoid conjugates occur in the systemic 8 circulation. Little is known about the nature and physiologically relevant concentrations of these 9 circulating conjugates, nor about species differences and interindividual human variation herein. 10 However, interpretation as well as design of both in vitro and in vivo animal and human 11 experiments would benefit from insight in the nature and physiologically relevant concentrations 12 of circulating conjugates. The aim of the present study was to use physiologically based kinetic 13 (PBK) modeling to predict the nature and regiospecificity of the major circulating metabolites 14 using quercetin as a model compound. 15 Quercetin is one of the most prevalent flavonoids in the human diet (e.g. onions) and also 16 one of the most widely studied flavonoids [5] . Upon absorption, quercetin aglycone can be 17 directly taken up in the small intestine by passive diffusion, but its glucoside needs to be 18 37ºC for 1 min. The reactions were terminated by adding 25 µl ice-cold acetonitrile:acetic acid 1 without the cofactor. The amount of glucuronide, sulfate and methyl conjugates formed, was 1 analyzed on a UPLC-DAD system consisting of a Waters (Milford, MA) Acquity binary solvent 2 manager, sample manager, and photodiode array detector, equipped with a Waters Acquity UPLC 3 BEH RP 18 column (1.7 μm, 2.1 x 50 mm). Before analysis, all samples were centrifuged at 4 18,600 x g for 5 min at 5ºC to precipitate proteins and 10 µl of the supernatant was immediately 5
analyzed. For glucuronide conjugates, a gradient of 2.5 mM ammonium acetate in nanopure 6 water (eluent A) and acetonitrile (eluent B), was used with a flow rate of 0.6 ml/min with the 7 following profile: 10-25% B (0-1.8 min); 25-90% B (1.8-2.5 min); 90% B (2.5-3.8 min); 90-10% 8 B (3.8-4 min) and 10% B (4-5 min). For sulfate and methyl conjugates, a gradient of nanopure 9 water containing 0.1% (v/v) trifluoroacetic acid (eluent A) and acetonitrile (eluent B) was used 10 with a flow rate of 0.6 ml/min with the following profile: 20-25% B (0-1.8 min); 25-35% B (1. [8] [9] [10] [11] 2.3 min); 35% B (2.3-2.8 min); 35-100% B (2.8-3 min); 100% B (3-4.1 min); 100-0% B (4.1-4.3 12 min); 0% B (4.3-5.5 min); 0-20% B (5.5-5.6 min) and 20% B (5.6-5. 8 
min). 13
The metabolites obtained from glucuronidation and sulfation were identified by 14 comparing the UV-spectra and the elution order of each metabolite with those reported in the 15 studies of Boersma et al. [16] and van der Woude et al. [17] as described previously for 16 incubations with rat tissue fractions [12] . The metabolites obtained from incubations measuring 17 methylation were identified by comparing the UV-spectra and the retention time with 18 commercially available standards of 3´-O-methylquercetin and 4´-O-methylquercetin. All 19 quercetin metabolites were quantified by integrating the peak areas at 370 nm and by using the 20 calibration curves of quercetin-3-O-glucuronide (for glucuronide conjugates), quercetin (for 21 sulfate conjugates), and 3′-O-methylquercetin and 4´-O-methylquercetin (for methyl conjugates). 22 23
LC-MS analysis 24
The nature of the formed metabolites from glucuronidation, sulfation and methylation ofWaltham, MA) coupled to an API 3000 system (Applied Biosystem, Foster city, CA). Aliquots of 1 10 µl were injected on an Agilent Zorbax Extend-C18 column, 2.1 x 50 mm, 3.5 Micron 80 Å 2 with a Zorbax guard column (Basel, Switzerland). The same gradient compositions as described 3 in Section 2.5 were used, except that eluent A was nanopure water containing 0.1% (v/v) acetic 4 acid and a flow rate of 0.2 ml/min was used with the following profile: 20% B (0-1 min), 20-35% 5 B (1-4 min), 35% B (4-6 min), 35-80% B (6-10 min), 80% B (10-15 min), 80-20% B (15-16 6 min), and 20% B (16-20 min). The mass spectrometric analysis was performed in the negative 7 ion mode using a spray voltage of 4.5 kV and a capillary temperature of 180ºC. The nebulizer gas 8 (air), curtain (nitrogen), declustering potential, focusing potential, and entrance potential were set 9 to 10, 8, -51, -200, and -13.7, respectively. Analysis was carried out using product ion (MS 2 ) 10 scanning from m/z 200-600. 11 12
Kinetic analysis 13
Kinetic parameters (i.e. apparent maximum velocity (V max(app) ) and apparent Michaelis-14
Menten constant (K m(app) )) for glucuronidation, sulfation, and methylation of quercetin were 15 determined by fitting the data to the standard Michaelis-Menten equation: 16 
Definition of the PBK model for (individual) human subjects 21
The PBK models that describe the absorption, distribution, metabolism and excretion 22 (ADME) of quercetin in (individual) humans were defined in a similar manner as used for 23 developing the previously defined PBK model for quercetin in male rats [12] . The structure of the 24 models is displayed in Figure 2 . The kinetic data describing metabolic conversion of quercetin to 25 its primary metabolites were obtained in the present study based on the in vitro experiments (seesection 3.1-3.3). Even though quercetin is one of the most studied flavonoids, there are only few 1 studies identifying and quantifying the plasma profiles of quercetin in humans [9] [10] [11] . Therefore, 2 we only used these studies for the development of the models. The parameters describing 3 excretion via urine, bile and intestinal enterocyte efflux back to lumen were fitted to the 4 available experimental human data [9] [10] [11] . These data are primary available for onion intake, 5 containing mainly Q4´Gly and quercetin-3,4´-O-diglucoside (Q34´diGly) [9, 10] and are 6 hydrolyzed to the aglycone by luminal lactase phlorizin hydrolase [18, 19] . Thus disappearance 7 of the glucosides to the aglycone in the intestinal lumen was included and fitted to the 8 experimental data, assuming each glucoside has its own deglycosylation rate with values ranging 9 from 0.51 -1 l/h and 0.01 -0.1 l/h for Q4´Gly and Q34´diGly, respectively. The uptake rate 10 constant of quercetin aglycone to the small intestine in humans was assumed to be similar to rats 11 with a value of 5.32 h -1 [20] . For the PBK model describing the ADME in an average human, the 12 kinetic constants obtained from incubations with pooled human tissue fractions were used. 13
Whereas for the PBK models in individual human subjects, the kinetic constants obtained with 14 the individual human liver fractions were used. No interindividual human variation in metabolism 15 by the small intestine was taken into account in the individual human models as the plasma 16 concentrations of quercetin metabolites is mainly influenced by the kinetic constants for 17 formation of primary metabolites in liver (see section 3.4). 18
For description of further conjugation of the primary metabolites to di-and tri-conjugates, 19 only further conjugation of different monoglucuronides was simulated since the glucuronide 20 metabolites were estimated to account for ~96% of the dose (see section 3.4). Lower catalytic 21 efficiencies for further glucuronidation, sulfation, and methylation of the monoglucuronides to diand tri-conjugates were assumed in comparison to the catalytic efficiencies for formation of the 23 respective mono-conjugates, due to both an increase in K m and a decrease in V max [12] . The 24 correction factors for further conjugation were obtained by fitting the predicted plasma AUC orconjugations into account, a total of 34 different mono-, di-and tri-conjugates could in theory be 1 expected and were thus included in the model. 2
The physiological parameters were obtained from the literature [21] and the partition 3 coefficients were calculated based on the methods described by DeJongh et al. [22] . The 4 physiological parameters and partition coefficients, thus obtained and used in the models are 5 summarised in Table 1 system. Mass balance equations for quercetin and its metabolites in tissues and blood were 8 similar to those previously described in the PBK model for quercetin in male rats [12] . Model 9 performance was assessed by comparing the predicted excretions via urine, bile and intestinal 10 enterocyte efflux back to lumen against available in vivo data [10, 23, 24] . With the obtained 11 model, the systemic bioavailability of quercetin aglycone and the nature and regiospecificity of 12 the major circulating quercetin metabolites in plasma were predicted. Conversion of the blood 13 concentrations of the different metabolites to plasma concentrations was done by dividing the 14 blood concentrations by a blood/plasma ratio (R). For quercetin and its metabolites a R value of 15 0.66 was applied and calculated using Simcyp prediction tools [25, 26] . The systemic 16 bioavailability of quercetin aglycone and the sensitivity analysis for the plasma AUC 0-24h of 17 quercetin metabolites were determined follow the methods previously described by Boonpawa et 18 al. [12] . The quercetin concentration dependent rate of formation of the monoglucuronides in these 10 incubations with pooled liver or small intestine S9 is shown in Figure 3A and 3B. For both 11 tissues, quercetin-3´-O-glucuronide was formed with the highest catalytic efficiency, which was 5 12 to 18-fold higher than the catalytic efficiency for formation of the other glucuronide conjugates in 13 these tissues (Table 3) . 14 Analysis of interindividual human variation in formation of monoglucuronides revealed 15 39-fold variation in the catalytic efficiencies for formation of these metabolites between the 20 16 individual human liver S9 samples that were analyzed (Table 4) 
Sulfation of quercetin by pooled and individual human tissue samples
Analysis of the incubations with pooled human liver and intestine S9 revealed that both 1 fractions were able to metabolize quercetin to sulfate conjugates. Quercetin-3´-O-sulfate was the 2 predominant sulfate metabolite formed in incubations with human intestine S9 and quercetin-7-3 O-sulfate was a minor metabolite. In incubations with human liver S9 only quercetin-3´-O-sulfate 4 was formed. The LC-MS results confirmed that the formed metabolites were quercetin sulfate as 5 all formed metabolites had an M -at m/z 381, which fragmented to produce m/z 301 (quercetin). 6
The quercetin concentration dependent rate of formation of the sulfate conjugates in these 7 incubations with pooled human liver or small intestine S9 is shown in Figure 3C and 3D and the 8 kinetic constants derived from these curves are displayed in Table 3 . 9
In incubations with individual human liver S9 also only quercetin-3´-O-sulfate was 10 formed, showing a 833-fold variation in formation of this metabolite between the different human 11 samples (Table 5 ). The highest catalytic efficiency was observed for individual H0251 (female, 12
Caucasian, 42 years), and the lowest for individual H0420 (male, Caucasian, 42 years). The 13 differences between these individuals were due to 13-and 76-fold variation in the V max and the 14 K m for sulfation respectively (Table 5) . 15 16
Methylation of quercetin by pooled and individual human tissue samples 17
Analysis of the incubations with pooled human liver and intestine S9 revealed that only 18 liver S9 was able to metabolize quercetin to methyl conjugates. In incubations with liver S9, both 19 3´-O-methylquercetin and 4´-O-methylquercetin were formed. The LC-MS results confirmed that 20 the formed metabolites were quercetin methyl conjugates as all formed metabolites had an M -at 21 m/z 315, which fragmented to produce m/z 301 (quercetin). Figure 3E shows the quercetin 22 concentration dependent rate of formation of methyl conjugates of quercetin in incubations with 23 human liver S9 fractions and the kinetic constants derived from these curves are displayed inyears) and the lowest in individual H0238 (male, African American, 3 months) ( Table 6 ). These 1 differences were mainly due to a ±80-fold higher K m for methylation by individual H0238. 2 3
Development of the (individual) human PBK models and evaluation of their performance 4
The kinetic constants obtained from in vitro incubations with pooled and individual 5 human tissue fractions were combined into PBK models to predict the bioavailability of quercetin 6 aglycone. The average predicted bioavailability of quercetin aglycone was 0.005% of the dose 7
and ranged between 0.001 and 0.04% of the dose for the individual human models at an average 8 dietary intake of 0.4 mg/kg bw quercetin. Quercetin was completely metabolized within 1.5 h for 9 all individuals and ~96% of the dose was converted to monoglucuronides. Among the mono-10
conjugates, quercetin-3´-O-glucuronide was predicted to be formed to the highest extent 11 accounting for 53 to 57% of the dose. 12
Further conjugation of different monoglucuronides to di-and tri-conjugates was 13 simulated. Because in vivo also quercetin-3´-O-sulfate has been detected in the plasma, the 14 formation of this metabolite was included in the comparison between the model predictions and 15 in vivo data, but given the low overall percentage of its formation (i.e < 3% of the dose), this 16 metabolite was not simulated to be subject to further conjugation. In general, the fitted models 17
showed comparable plasma levels of metabolites to the levels reported in literatures (i. Table 7 . 24
With the adequate predictions of the plasma levels of the different metabolites obtainedcomparing the predicted excretion of quercetin metabolites via urine, bile and intestinal 1 enterocyte efflux back to lumen to the reported levels in vivo [10, 23, 24] . Figure 5 shows that the 2 models adequately predicted urinary profiles with 1 to 4-fold and 1 to 7-fold accuracy 4 h and 24 3 h after consumption of onions corresponding to dose levels of 0.46 mg/kg bw Q4´Gly and 0.49 4 mg/kg bw Q34´diGly [23] and 0.95 Q4´Gly and 0.96 mg/kg bw Q34´diGly [10] . After 72 h 5 following consumption of 1.4 mg/kg bw 14 C-quercetin, 3.5 to 5.7% of the dose was recovered in 6 the urine which is 1 to 2-fold lower than the model prediction of 7.5% of the dose at the same 7 dose [24]. In the same study 52.1 ± 6.4% of the dose was recovered as 14 CO 2 in the expired air. 8
This value can be used to evaluate the biliary excretion and intestinal efflux back to lumen, 9 because 14 CO 2 is likely a product of microorganisms present in the intestinal lumen [27] . The 10 predicted biliary excretion (74% of the dose) together with intestinal enterocyte efflux back to 11 lumen (16% of the dose) is 2-fold higher than the reported CO 2 level in vivo at the same dose. 12
The key parameters that influence the predicted plasma AUC 0-24h of all quercetin 13 metabolites in human at a dose of 0.4 mg/kg bw quercetin were assessed and are shown in Figure  14 6. The plasma AUC 0-24h of quercetin metabolites are mainly influenced by parameters 15 determining concentration in liver, namely liver volume, biliary excretion rate constant and S9 16 protein content in liver. The blood/plasma ratio is also found to have a great influence on the 17 prediction as it determines the concentration of metabolites in plasma. The kinetic parameters for 18 formation of mono-conjugates especially in the liver as well as the correction factors for the V max 19 and the K m for formation of di-and tri-conjugates, have an influence on the plasma AUC 0-24h of 20 quercetin metabolites. Other parameters including partition coefficients and blood flow rates to 21 tissue do not have an effect on the predicted plasma AUC 0-24h of quercetin metabolites. 22 23 Figure 7 shows the predicted regiospecificity of the six metabolites with the highestmg/kg bw quercetin (average supplementary intake), including interindividual human variation 1 and species differences. At a dose of 0.4 mg/kg bw, quercetin-3´-O-glucuronide was predicted to 2 be the major metabolite for 19 out of 20 individual human subjects accounting for 19 to 42% of 3 the total plasma AUC 0-24h ( Figure 7A ). However, individual H0270 (male, Caucasian, 5 months) 4 that expressed a high level of glucuronidation at the 3-OH, was predicted to have mainly 5 quercetin-3,3´-O-diglucuronide in the plasma accounting for 43% of the total plasma AUC 0-24h . 6
Model simulations 24
At a dose of 12 mg/kg bw quercetin, quercetin-3´-O-glucuronide becomes the major metabolite 7 for all individuals ( Figure 7B ) due to saturation of other reactions at higher dose levels. 8
Comparison of the predicted levels of the major circulating metabolites of quercetin in 9 humans to those previously predicted for male rats revealed major species differences in 10 circulating metabolites [12] . In male rats a di-and tri-conjugate of quercetin containing a 11 glucuronic acid, sulfate and/or methyl moiety were predicted to be the major circulating 12 metabolites of quercetin at both average dietary and supplementary intake. The differences 13 between male rats and human in regiospecificity of circulating metabolites were especially a 14 result of the catalytic efficiency and regioselectivity, which the primary metabolites are formed 15 (Table 7) . 16 Mullen et al. in which quercetin-3´-O-glucuronide and di-and tri-conjugates containing 2 a glucuronide moiety were the major metabolites in the urine after consumption of onions [10] . 3 However, these metabolites were not observed to be the major metabolites in the plasma, which 4 was observed to mainly contain quercetin-3´-O-sulfate [10] . A more recent study by Lee et al., , 5 revealed that quercetin conjugates containing glucuronide moiety are the most important 6 metabolites present in human plasma, when quantified with LC-MS in positive ion mode [9] . In 7 the study of Lee et al. the regiospecificity of these metabolites was not determined, and the 8 importance of especially quercetin-3´-O-glucuronide as a major circulating can therefore not be 9 confirmed based on this study. 10
Interindividual human variation was observed in the kinetic constants for glucuronidation, 11 sulfation and methylation as determined with the incubations performed with the 20 individual 12 human liver fractions of the present study (Table 4- individual. These results may suggest that especially and genetic-and lifestyle factors influencing 22 the expression and/or activity of UGT enzymes involved in quercetin glucuronidation, including 23 UGT1A1, UGT1A3, UGT1A8, UGT1A9, and UGT2B7 may influence the regiospecificity ofWith the developed PBK models for quercetin in (individual) human subjects and the 1 previously defined model for rats, also species differences in metabolism of quercetin could be 2 evaluated. Whereas the major predicted circulating metabolites of quercetin in humans are 3 monoglucuronides and predominantly quercetin-3´-O-glucuronide, the major circulating 4 metabolites in rats were di-and tri-conjugates containing glucuronic acid, sulfate and/or methyl 5 moiety ( Figure 7 ). These differences are partly due to a 2.3-fold higher metabolic conversion in 6 rats as compared with humans, resulting in a faster further conversion of the monoglucuronides. 7
A higher rate of glucuronidation in rats compared with human is more commonly observed. . Also species differences in the tentatively identified 17 regiospecificity of circulating metabolites were observed, as rats mainly show primary 18 glucuronidation at the 4´-OH and humans at the 3´-OH and di-and tri-conjugates building further 19 on these different mono-conjugates in both species. This differences in conversion of flavonoids 20 may be a result of differences in the size and shape of the binding pocket of different enzymes 21 involved in the reactions [35] . Glucuronidation of quercetin in humans has been identified to be 22 catalyzed by UGT1A1, UGT1A8 and UGT1A9 based on incubations with recombinant enzymes 23
[16], whereas glucuronidation in rats has been linked to UGT1A1 and UGT1A7 activity in an in [35] . A difference in contribution of this enzyme to the total glucuronidation activity between the 1 two species might therefore explain the observed differences in primary metabolites that are 2 formed and consequently the secondary and tertiary metabolites that build upon these primary 3 glucuronides. 4
Considering that the nature and the position of flavonoid conjugation could be a key 5 factor determining biological activity of flavonoids in vivo [37] , the observed differences between 6 individual human subjects in circulating metabolites could indicate critical differences in 7 sensitivity to health beneficial effects. In addition, the differences between rats and humans may 8 suggest that the biological effects of flavonoids observed in rats may not necessary be relevant 9 for the human situation. At present little is known about the biological activity of flavonoid 10 metabolites. Metabolism does not always result in a reduced biological activity of flavonoids 11
[37]. In addition, biological activity might be a result of the extent by which the flavonoids are 12 
